Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART)

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 5, 2001, Pages 405-415

  Morris, Mary Kate ^a,b   Katzenstein, David A ^c   Israelski, Dennis ^c,d   Zolopa, Andrew ^c   Hendry, R Michael ^a   Hanson, Carl V ^a  

^a VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d San Mateo County Health System   (United States)

Author keywords

HAART; HIV; Humoral immune response; Neutralizing antibody response

Indexed keywords

ANTIRETROVIRUS AGENT; ENVELOPE PROTEIN; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; V3 PEPTIDE;

ADULT; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS ENVELOPE; VIRUS LOAD;

EID: 0035894059     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200112150-00001     Document Type: Article

References (40)

1. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: Results of a 6 year prospective study
2. Toward an HIV type 1 vaccine that generates potent, broadly cross- reactive neutralizing antibodies
3. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection
4. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man
5. Genetic analysis of HIV-1 during rapid progression to AIDS in an apparently healthy man
6. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
7. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
8. Treatment history and baseline viral load, but not viral tropism or CCR- 5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment
9. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
10. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens
11. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors
12. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
13. Levels of human immunodeficiency virus type 1-specific cytotoxic T- lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
14. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
15. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection
16. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
17. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection
18. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy
19. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
20. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
21. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
22. Antigen requirements, sensitivity, and specificity of enzyme immunoassays for measles and rubella viral antibodies
23. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
24. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
25. Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers
26. Use of V3 loop peptide-specific antibody evaluation for subtyping HIV- 1: Results of a vertical rransmission study from Sao Paulo, Brazil
27. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
28. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
29. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment
30. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
31. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
32. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
33. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects
34. Exploring the benefits and limits of highly active antiretroviral therapy
35. Restored humoral immune response to influenza vaccination in HIV- infected adults treated with highly active antiretroviral therapy
36. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
37. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
38. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population
39. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy
40. Quantitative image analysis of HIV-1 infection in lymphoid tissue